Canine subcutaneous mast cell tumor: Characterization and prognostic indices

Veterinary Pathology

Volumn 48, Issue 1, 2011, Pages 156-168

  Thompson, J J ^a   Pearl, D L ^a   Yager, J A ^b   Best, S J ^b   Coomber, B L ^a   Foster, R A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b YagerBest Histological and Cytological Services   (Canada)

Author keywords

Canine; Cox proportional hazards; Mast cell tumor; Mitotic index; Survival

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; FEMALE; MALE; MASTOCYTOMA; PATHOLOGY; PROGNOSIS; SOFT TISSUE TUMOR; TIME;

ANIMALS; DOG DISEASES; DOGS; FEMALE; MALE; MASTOCYTOMA; PROGNOSIS; SOFT TISSUE NEOPLASMS; TIME FACTORS;

CANIS FAMILIARIS;

EID: 79951872360     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985810387446     Document Type: Article

References (55)

1. Abadie JJ, Amardeilh MA, Delverdier ME: Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 215:1629-1634, 1999.
2. Al-Sarraf R., Mauldin GN, Patnaik AK, Meleo, KA: A prospective study of radiation therapy for the treatment of grade 2 mast cell tumours in 32 dogs. J Vet Intern Med 10:376-378, 1996.
3. Bostock DE: Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 142:1-19, 1986.
4. Bostock DE: The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 14:27-41, 1973.
5. Bostock DE, Crocker J., Harris K., Smith P.: Nucleolar organizer regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 59:915-918, 1989.
6. Chaldakov GN, Stankulov IS, Hristova M., Ghenev PI: Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 9:1023-1031, 2003.
7. Chaldakov GN, Tonchev AB, Tuncel N., Atanassova P., Aloe L.: Adipose tissue and mast cells: adipokines as yin-yang modulators of inflammation. In: Adipose Tissue and Adipokines in Health and Disease, ed. Gantuzzi G and Mazzone T, pp. 151-158. Totowa, NJ, Humana Press, 2007.
8. Cleary MP, Grossmann ME, Ray A.: Effect of obesity on breast cancer development. Vet Pathol 47:202-213, 2010.
9. Downing S., Chien MB, Kass PH, Moore PE, London CA: Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 63:1718-1723, 2002.
10. Elston LB, Sueiro FA, Cavalcanti JN, Metze K.: The importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study. Vet Pathol 46:362-365, 2009.
11. Fulcher RP, Ludwig LL, Bergman PJ, Newman SJ, Simpson AM, Patnaik AK: Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 228:210-215, 2006.
12. Galli SJ: New concepts about the mast cell. N Engl J Med 328:257-265, 1993.
13. Galli SJ: New insights into "the riddle of the mast cells": micro-environmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 62:5-33, 1990.
14. Galli SJ, Kalesnikoff J., Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M.: Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23:749-786, 2005.
15. Gil da Costa RM, Matos E., Rema A., Lopes C., Pires MA, Gartner F.: CD117 immunoexpression in canine MCT: correlations with pathological variables and proliferation markers. BMC Vet Res 3:1-7, 2007.
16. Gross TL, Ihrke PJ, Walder EJ, Affolter VK: Mast cell tumors. In: Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis, ed. Gross TL, Ihrke PJ, Walder EJ, Affolter VK, 2nd ed., pp. 853-865. Oxford, UK, Blackwell Science Ltd, 2005.
17. Kiupel M., Webster JD, Kaneene JB, Miller R., Yuzbasiyan-Gurkan V.: The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 41:371-377, 2004.
18. Kiupel M., Webster JD, Miller RA, Kaneene JB: Impact of tumor depth, tumor location and multiple synchronous masses on the prognosis of canine cutaneous MCT. J Vet Med A Physiol Pathol Clin Med 52:280-286, 2005.
19. Kravis LD, Vail DM, Kisseberth WC, Ogilvie GK, Volk LM: Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. J Am Vet Med Assoc 209:1418-1420, 1999.
20. Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal PS, Guéry S., Moussy A., Kinet JP, Hermine O., Dubreuil P.: Gain of function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 6:1137-1145, 2008.
21. Lin TY, Bear M., Du A., Foley KP, Ying W., Barsoum J., London CA: The novel HSP90 inhibitor STA-9090 exhibits activity against kit-dependent and -independent malignant mast cell tumors. Exp Hematol 36:1266-1277, 2008.
22. Lin TY, Thomas R., Tsai PC, Breen M., London CA: Generation and characterization of novel canine malignant mast cell line CL1. Vet Immunol Immunopathol 127:114-124, 2009.
23. Lin WW, Karin M.: A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 117:1175-1183, 2007.
24. London CA, Galli SJ, Yuuki T., Hu ZQ, Helfand SC, Geissler EN: Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27:689-697, 1999.
25. London CA, Seguin B.: Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 33:473-489, 2003.
26. Ma Y., Longley BJ, Wang X., Blount JL, Langley K., Caughey GH: Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 112:165-170, 1999.
27. Maglennon GA, Murphy S., Adams V., Miller J., Smith K., Blunden A., Scase TJ: Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Vet Comp Oncol 6:268-274, 2008.
28. Maiolino P., Cataldi M., Paciello O., Restucci B., De Vico G.: Nucleomorphometric analysis of canine cutaneous mast cell tumours. J Comp Pathol 133:209-211, 2005.
29. McNiel EA, Prink AL, O'Brien TD: Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol 4:2-8, 2006.
30. Michels GM, Knapp DW, DeNicola DB, Glickman N, Bonney P: Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 38:458-466, 2002.
31. Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH, Lana SE: Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 228:91-95, 2006.
32. Nechushtan H.: The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol 42:551-554, 2010.
33. Newman SJ, Mrkonjich L., Walker KK, Rohrbach BW: Canine subcutaneous mast cell tumour: diagnosis and prognosis. J Comp Pathol 136:231-239, 2007.
34. Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP, Garcia A., Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Cheng AL, Howerth EW: Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 17:245-248, 2005.
35. Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal KP, Garcia AP, Latimer KS, Munday JS, Rakich PM, Richey LJ, Stedman NL, Gieger TL: Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. J Vet Diagn Invest 17:561-564, 2005.
36. Ozaki K., Yamagami T., Nomura K., Narama I.: Prognostic significance of surgical margin, Ki-67 and cyclin D1 protein expression in grade II canine cutaneous mast cell tumor. J Vet Med Sci 69:1117-1121, 2007.
37. Patnaik AK, Ehler WJ, MacEwen EG: Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 21:469-474, 1984.
38. Pistollato F., Abbadi S., Rempazzo E., Persano L., Puppa AD, Frasson C., Sarto E., Scienza R., D'avella D., Basso G.: Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28:851-862, 2010.
39. Preziosi R., Sarli G., Paltrinieri M.: Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Vet Res Commun 31:287-296, 2007.
40. Preziosi R., Sarli G., Paltrinieri M.: Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog. J Comp Pathol 130:143-151, 2004.
41. Rebuzzi L., Willmann M., Sonneck K., Gleixner KV, Florian S., Kondo R., Mayerhofer M., Vales A., Gruze A., Pickl WF, Thalhammer JG, Valent P.: Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115:320-333, 2007.
42. Riva F., Brizzola S., Stefanello D., Crema S., Turin L.: A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 17:385-388, 2005.
43. Romansik EM, Reilly CM, Kass PH, Moore PF, London CA: Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol 44:335-341, 2007.
44. Sakai H., Noda A., Shirai N., Iidaka T., Yanai T., Masegi T.: Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression. J Comp Pathol 127:233-238, 2002.
45. Scase TJ, Edwards D., Miller J., Henley W., Smith K., Blunden A., Murphy S.: Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 20: 151-158, 2006.
46. Séguin B., Besancon MF, McCallan JL, Dewe LL, Tenwolde MC, Wong EK, Kent MS: Reoccurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med 20:933-940, 2006.
47. Séguin B., Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ, Withrow SJ: Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 218:1120-1123, 2001.
48. Sfiligoi G., Rassnick KM, Scarlett JM, Northrup NC, Gieger TL: Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001). J Am Vet Med Assoc 226:1368-1374, 2005.
49. Simoes JP, Schoning P., Butine M.: Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 31:637-647, 1994.
50. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA, Patnaik AK: Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 224:236-240, 2004.
51. Strefezzi Rde F., Xavier JG, Cãtao-Dias JL: Morphometry of canine cutaneous mast cell tumors. Vet Pathol 40:268-275, 2003.
52. Webster JD, Yuzbasiyan-Gurkan V., Miller RA, Kaneene JB, Kiupel M.: Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 44:298-308, 2007.
53. Weisse C., Shofer FS, Sorenmo K.: Reoccurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 38:71-73, 2002.
54. Zavodovskaya R., Chien MB, London CA: Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J Vet Intern Med 18:915-917, 2004.
55. Zemke D., Yamini B., Yuzbasiyan-Gurkan V.: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 39:529-535, 2002.